Liver-derived tumor cell growth inhibitor
US5393534A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 9, 1992 |
| Grant date | Feb 28, 1995 |
| Priority date | — |
| Expiry date | Apr 9, 2012 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/846
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A factor has been purified from rat liver homogenate which displays preferential growth inhibitory effects on non-liver metastasizing tumor cells. The purification steps include heat treatment, ammonium sulfate precipitation, anion exchange chromatography, hydrophobic interaction chromatography, cation exchange chromatography, gel filtration chromatography, and preparative isoelectric focusing. The growth inhibitor obtained has an apparent M.sub.r of 38 kD to 40 kD and a pI of 9.1, it is not affected by reducing agents, and displays no biological TGF-b activity. This inhibitor exhibits less antiproliferative effect on liver metastasizing cells than on their non-liver metastasizing counterparts in two tumor systems: the murine RAW117 large cell lymphoma, and the human A375 melanoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.